Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura L Fernandes

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Cancer Medicine|April 10, 2024
Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapyHelmneh M Sineshaw, Christina M Zettler, Jennifer Prescott, et al.
JCO Clinical Cancer Informatics|April 16, 2025
Validation of a Composite Real-World Mortality Variable Among Patients With Hematologic Malignancies Treated in the United StatesSharlene Dong, Ankit Kansagra, Gurbakhash Kaur, et al.
Blood Advances|February 3, 2022
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trialsBindu Kanapuru, Laura L Fernandes, Lola A Fashoyin-Aje, et al.
Blood Neoplasia|June 23, 2025
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United StatesMatthew S Davids, Jacob Ambrose, Enrico de Nigris, et al.
JCO Oncology Practice|May 9, 2025
Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based TherapyCurtis A Lachowiez, Anna Barcellos, Christina M Zettler, et al.
Blood Cancer Journal|April 20, 2022
Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world dataKathleen Maignan, Lola A Fashoyin-Aje, Aracelis Z Torres, et al.
JCO Oncology Practice|April 30, 2026
Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United StatesElizabeth Dianne Pulte, Laura L Fernandes, Kelly Norsworthy, et al.
The Oncologist|December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
American Journal of Hematology|December 13, 2025
Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p DeletionRebecca Bystrom, Laura L Fernandes, Joseph Wynne, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cancer Medicine|April 10, 2024
Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapyHelmneh M Sineshaw, Christina M Zettler, Jennifer Prescott, et al.
JCO Clinical Cancer Informatics|April 16, 2025
Validation of a Composite Real-World Mortality Variable Among Patients With Hematologic Malignancies Treated in the United StatesSharlene Dong, Ankit Kansagra, Gurbakhash Kaur, et al.
Blood Advances|February 3, 2022
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trialsBindu Kanapuru, Laura L Fernandes, Lola A Fashoyin-Aje, et al.
Blood Neoplasia|June 23, 2025
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United StatesMatthew S Davids, Jacob Ambrose, Enrico de Nigris, et al.
JCO Oncology Practice|May 9, 2025
Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based TherapyCurtis A Lachowiez, Anna Barcellos, Christina M Zettler, et al.
Blood Cancer Journal|April 20, 2022
Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world dataKathleen Maignan, Lola A Fashoyin-Aje, Aracelis Z Torres, et al.
JCO Oncology Practice|April 30, 2026
Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United StatesElizabeth Dianne Pulte, Laura L Fernandes, Kelly Norsworthy, et al.
The Oncologist|December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
American Journal of Hematology|December 13, 2025
Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p DeletionRebecca Bystrom, Laura L Fernandes, Joseph Wynne, et al.
Pageof 3